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Constitutive egress of bone marrow (BM)-resi-
dent hematopoietic stem and progenitor cells
(HSPCs) into the blood is a well-established
phenomenon, but the ultimate fate and func-
tional relevance of circulating HSPCs is largely
unknown. We show that mouse thoracic duct
(TD) lymph contains HSPCs that possess short-
and long-term multilineage reconstitution ca-
pacity. TD-derived HSPCs originate in the BM,
enter the blood, and traffic to multiple periph-
eral organs, where they reside for at least 36 hr
before entering draining lymphatics to return to
the blood and, eventually, the BM. HSPC egress
from extramedullary tissues into lymph de-
pends on sphingosine-1-phosphate receptors.
Migratory HSPCs proliferate within extramedul-
lary tissues and give rise to tissue-resident my-
eloid cells, preferentially dendritic cells. HSPC
differentiation is amplified upon exposure to
Toll-like receptor agonists. Thus, HSPCs can
survey peripheral organs and can foster the
local production of tissue-resident innate im-
mune cells under both steady-state conditions
and in response to inflammatory signals.
INTRODUCTION
Most differentiated cells found in mammalian blood have
variable but limited life spans and must be constantly
replenished. Blood cell homeostasis depends on a rare
population of precursor cells, the hematopoietic stem
cells (HSCs), which possess the unique capacity for self-
renewal and multilineage differentiation. The function of
HSCs and the partially lineage-committed progenitor cells
that arise from them has been linked to their migratory
properties, at least during fetal life, when the anatomic
seat of hematopoietic activity changes several times
(Cumano and Godin, 2007).994 Cell 131, 994–1008, November 30, 2007 ª2007 Elsevier IncIn postnatal mammalian life, hematopoietic stem and
progenitor cells (HSPCs) reside mostly in specialized
niches in bone marrow (BM) cavities that control HSPC
survival, proliferation, self-renewal, and differentiation
(Adams and Scadden, 2006). However, even in adulthood,
HSPCs are not entirely sessile but contain a population of
highly migratory cells. It is well established that some
HSPCs recirculate constantly between BM and blood
(Goodman and Hodgson, 1962; Wright et al., 2001b). Ac-
cordingly, normal blood from adult mice contains a small
but stable population of several hundred HSPCs, which
upon transplantation to irradiated recipients are capable
of the long-term reconstitution (LTR) of hematopoietic ac-
tivity (Fleming et al., 1993; Morrison et al., 1997). It has
been speculated that the continuous trafficking of HSPCs
between BM and blood is a mechanism to maintain full
occupancy of HSPC niches in all BM cavities (Wright
et al., 2001b). However, the exact trafficking pathways
of blood-borne HSPCs and the physiological relevance
of their postnatal migration remain largely unclear.
The daily turnover of HSPCs that enter and leave the
bloodstream is believed to be high (Wright et al., 2001b).
The BM is probably not the exclusive physiological source
and destination of blood-borne HSPCs because HSPCs
have also been recovered from extramedullary sites, like
the liver (Cardier and Barbera-Guillem, 1997), spleen
(Wright et al., 2001b), and muscle (McKinney-Freeman
et al., 2002). Therefore, although we know little about the
migratory dynamics of extramedullary HSPCs, it seems
likely that circulating HSPCs visit anatomic regions other
than the BM. A case in point is the trafficking of mature
lymphocytes, which extravasate continuously into multi-
ple lymphoid and nonlymphoid tissues. Most tissue-
resident lymphocytes eventually return to the blood via
lymphatics that drain into the thoracic duct (TD). This lym-
phocyte recirculation is essential for immunosurveillance
because it maximizes the probability that lymphocytes
encounter rare cognate antigens (von Andrian and
Mackay, 2000).
Here, we have examined whether blood-borne HSPCs
might follow similar extramedullary traffic patterns as
lymphocytes. We demonstrate that efferent lymphatics.
Figure 1. Clonogenic HSPCs Travel in TD Lymph
(A) FACS analysis of TD MNCs. Numbers show the frequency of gated cells among total MNCs. No events where detected in the LSK gate with
isotype-matched control antibodies (data not shown).
(B) Concentration of CFU-Cs in normal mouse PB and TD lymph. Columns and error bars represent mean ± SEM, n = 12–23 assays (from 6–12
animals), and circles represent results from individual assays.
(C) Absolute (left) and relative frequencies (right) of CFU-Cs in total MNCs or sorted Lin+, Linc-Kit, and Linc-Kit+ TD cells. Mean ± SEM are
presented (n = 4–16 assays, mean ± SEM). Right panel: Representative micrographs of Linc-Kit+ TD-derived CFU-Cs, defined by the presence
of granulocytes, macrophages, erythroid cells and megakaryocytes as CFU-granulocyte (CFU-G), CFU-macrophage (CFU-M), CFU-granulocyte,
macrophage (CFU-GM), CFU-granulocyte, erythroid, macrophage, megakaryocyte (CFU-GEMM), respectively. Scale bars represent 50 mm.contain a stable fraction of HSPCs that possess short- and
long-termmultilineage reconstitution capacity. TD HSPCs
originate in the BM and traffic constitutively to multiple
extramedullary, nonlymphoid tissues, where they reside
for at least 36 hr until entering the draining lymphatics to
return to the blood. This recirculation of HSPCs is regu-
lated, in part, by the S1P receptor S1P1 and might foster
the local production of tissue-resident innate immune cells
under both steady-state conditions and in response to
infections.
RESULTS
Lin Hematopoietic Cells Travel in the TD
We surmised that if HSPCs recirculate through extramye-
loid tissues, then they, like differentiated lymphocytes,Celmight become lymph borne. Indeed, lymph fluid collected
from murine TD (see the Supplemental Experimental Pro-
cedures in the Supplemental Data available with this arti-
cle online) contained up to 4% mononuclear cells (MNCs)
that expressed the pan-leukocyte antigen CD45 but no
other hematopoietic lineage markers (Figure 1A). This
population included LinIL-7Ra+c-Kit+Sca-1+ (0.003%–
0.004% of all TD MNCs) and LinIL-7Rac-Kit+Sca-1
cells (0.01%–0.03% of all TD MNCs), resembling the
phenotype of committed BM common lymphoid (CLP)
(Kondo et al., 1997) and common myeloid (CMP) progen-
itor cells (Akashi et al., 2000), respectively (Figure S1). In
addition, CD45+ LinIL-7Ra TD cells included cells with
a primitive HSC and/or multipotent progenitor (MPP) phe-
notype (LinIL-7Rac-Kit+Sca-1+ [LSK]) (Christensen and
Weissman, 2001), which amounted to 0.001%–0.004% ofl 131, 994–1008, November 30, 2007 ª2007 Elsevier Inc. 995
Figure 2. TD Lymph HSPCs Possess Long-Term Multilineage Repopulation Capacity
(A) TD-derived CD45.2+ MNCs (23 107) were injected into sublethally irradiated CD45.1+ recipients. Chimerism among total MNC and Gr-1+ cells in
PB was determined by FACS 6 weeks after transplantation (n = 6).
(B) TCR-b+ T cells are found in PB of WT mice (first column) but not in nude (second column) or Rag2/gc/ mice (third column). Transfer of TD
MNCs (2 3 107) from nude mice into lethally irradiated Rag2/gc/ mice restored T cells in Rag2/gc/ recipients (fourth column). Numbers
show the frequency of CD8a+ TCR-b+ and CD8a (mostly CD4+) TCR-b+ cells among MNCs. Data are representative of two experiments.996 Cell 131, 994–1008, November 30, 2007 ª2007 Elsevier Inc.
CD45+ TD MNCs (Figure 1A and Figure S1). Lymph-de-
rived LSK cells expressed several adhesion and traffic
molecules, including CXCR4, CD44, PSGL-1, and LFA-
1, as well as a4 and a5 integrins (Table S1). Methylcellu-
lose-based colony-forming unit culture (CFU-C) assays
of MNCs from blood and TD confirmed that both compart-
ments contain clonogenic HSPCs (Figure 1B). Notably, no
significant differences were observed in the number of
CFU-Cs in peripheral blood collected 6, 12, or 24 hr after
surgery or with control blood (without surgery), implying
that the collection of thoracic duct lymph per se did not in-
duce the enhanced mobilization of HSPCs (data not
shown). Clonogenic cells mostly resided within the
Linc-Kit+ population of TD cells, whereas Lin+ or Linc-
Kit TD cells gave rise to no or few colonies in CFU-C as-
says, respectively (Figure 1C). When lymph was collected
from irradiated wild-type (WT) mice reconstituted with BM
from green fluorescent protein (GFP)-transgenic donors
(Wright et al., 2001a), virtually all of the colonies expressed
GFP, indicating that the lymph-borne HSPCs are BM de-
rived (Figure S2A). On average, we measured a TD lymph
flow of 0.78 ± 0.05 ml/hr, and each ml of lymph contained
4.9 ± 0.8 CFU-C. Considering that TD lymph constitutes
only 50% of total body lymph flow, we estimate that
200 clonogenic HSPCs pass through the lymph of
a mouse every day. This number is substantial considering
the fact that a single HSC can reconstitute the entire hema-
topoietic system of a mouse (Wagers et al., 2002) and that
the infusion of as few as 30 of these cells is sufficient to
save 50% of lethally irradiated mice and to reconstitute
all blood cell types in the survivors (Spangrude et al., 1988).
Lin TD Cells Have BM Homing Capacity
To define whether lymph-borne Lin cells share the abil-
ity of blood-derived HSPCs to home to the BM, we in-
jected fluorescently tagged Lin TD cells intravenously
into mice, and their presence in recipient tissues was
assessed by flow cytometry 24 hr later. Irrespective of
whether recipients were preconditioned by irradiation,
donor Lin cells were detectable in recipient BM and
spleens (Figure S2B). Multiphoton intravital microscopy
of skull BM (Mazo et al., 2005) in anesthetized recipients
confirmed that Lin TD-derived cells can migrate into
BM cavities within 12–24 hr after adoptive transfer
(Figure S2C, Movies S1–S3).
HSPCs with Short- and Long-Term Multilineage
Reconstitution Capacity Travel in the TD Lymph
So that the functional engraftment capacity of lymph-
borne HSPCs could be explored, TD MNCs from
CD45.2+ donors were transplanted into sublethally irradi-Celated CD45.1+ congenic recipients. After 6 weeks, 15%
of Gr-1+ peripheral blood granulocytes were donor
derived (Figure 2A), indicating that lymph-borne HSPCs
possess myeloid differentiation potential (Morrison and
Weissman, 1994; Wright et al., 2001b). To test whether
they also give rise to T cells, we harvested TD MNCs
from athymic B6nude/nude mice, which lack mature T cells,
although their HSPCs can give rise to T cells when trans-
planted to thymus-sufficient animals. B6nude/nude TD
MNCs were injected into lethally irradiated Rag2/gc/
mice, which possess a functional thymic anlage but are
genetically incapable of generating lymphocytes (Gold-
man et al., 1998). Remarkably, 6 weeks after transplanta-
tion, Rag2/gc/ recipients of B6nude/nude TDMNCs had
a near-normal T cell compartment (Figure 2B). To address
whether lymph-borne HSPCs contain multipotent HSCs
with persistent self-renewal capacity, we transplanted
CD45.2+ TD MNCs into lethally irradiated CD45.1+ recipi-
ents, which were sacrificed 12 weeks later. CD45.2+ cells
were then sorted from the first recipients’ BM and trans-
planted into another CD45.1+ recipient (Figure 2C). Ten
weeks after the secondary transplantation, the recipient
showed multilineage reconstitution by CD45.2+ cells.
Hence, normal murine lymph contains long-termmultiline-
age repopulating HSPCs that meet the phenotypic and
functional criteria of true HSCs.
HSPCs Do Not Require Lymphoid Structures
for Recirculation
HSPCs travel between blood and lymph similar to naive
lymphocytes. Hence, both populations might share transit
routes guiding them from blood into lymphatics. Naive
lymphocytes must home to lymph nodes and Peyer’s
patches (PPs) to gain access to lymph vessels (von
Andrian and Mackay, 2000). Consequently, MNCs were
dramatically reduced in lymph of lymphotoxin (LT)-a defi-
cient mice (Figure 3A), which lack these lymphoid tissues
(De Togni et al., 1994). However, HSPCs were still present
in the TD lymph of LT-a/ mice, as assessed by fluores-
cence-activated cell sorting (FACS) (data not shown) or
CFU-C assays (Figure 3B). Thus, HSPCs, unlike lympho-
cytes, do not require secondary lymphoid organs (SLOs)
to recirculate but might traffic directly to the lymph from
extramedullary nonlymphoid tissues.
HSPCsContinuously Travel from theBM toVarious
Extramedullary Tissues
To define where and how HSPCs might leave the blood
and pass through extramedullary tissues into the lymph,
we first surveyed different murine tissues for the presence
of HSPCs by using CFU-C assays. Clonogenic(C) CD45.2+ TD-MNCs (23 107) were transplanted into sublethally irradiated CD45.1+ primary recipients. Twelve weeks later, chimerism among PB
granulocytes (Gr-1+) was determined (left column). Analysis of CD45.2+ cells in BM (middle column) demonstrates the persistence of a Lin subset,
which includes LSK cells (indicated by circle in bottompanel). Twelve weeks after the primary transplantation, the CD45.2+ CD45.1 cells were sorted
out of the primary recipient’s BM and transplanted into a lethally irradiated CD45.1+ secondary host (right column). Chimerism among PB granulo-
cytes (Gr-1+), T cells (CD8+TCR-b+), and B cells (B220+) was assessed by FACS 12 weeks after the secondary transplantation. Numbers show the
frequency of cells in the individual quadrants.l 131, 994–1008, November 30, 2007 ª2007 Elsevier Inc. 997
Figure 3. Secondary Lymphoid Organs Are Not Required for Recirculation of HSPCs across Extramedullary, Nonlymphoid Tissues
CFU-C assays were performed with TD MNCs collected from WT or LT-a/mice. (A) shows the concentration of MNC in lymph (n = 6–12 animals);
(B) shows the relative (left) and absolute (right) frequencies of CFU-Cs among lymph-borneMNCs (n = 14–28 assays). Error bars represent the mean ±
the SEM.progenitors were detectable inmany tissues, including the
lung, liver, small intestine, kidneys, and blood, but CFU-Cs
were rare or absent in cardiac and skeletal muscle, skin,
and LNs (Figure S3). It should be noted that we counted
the number of colonies 7 days after the plating of the cells
in methylcellulose to detect primitive HSPCs with large
burst size. Therefore, our data do not account for the pres-
ence of late-outgrowth (more committed) progenitors, that
have been reported to reside within some tissues, includ-
ing peripheral LNs (MacVittie and McCarthy, 1977). Vir-
tually all clonogenic tissue HSPCs were BM derived
because colonies uniformly expressed GFP in chimeric
wild-type recipients of GFP+ BM (data not shown). More-
over, the transplantation of liver-derived CFU-Cs into irra-
diated recipients resulted in multilineage reconstitution,
indicating that at least in some organs, clonogenic cells
possess multilineage reconstitution capacity (data not
shown). On the basis of the yield of CFU-Cs in surveyed
organs, we estimate the total number of HSPCs resident
in extramedullary nonlymphoid tissue to be at least twice
as large as the average number of HSPCs circulating in
murine blood (Wright et al., 2001b).
Next, we generated pairs of parabiotic mice, in which
one partner ubiquitously expressed GFP. Consistent
with previous reports (Wright et al., 2001b), crosscircula-
tion was established by day 3 after surgical joining, and
the host:partner (i.e. GFP+:GFP) ratio of both mature
leukocytes and CFU-C in blood plateaued at 3:2 (cor-
responding to 40% chimerism) between days 10 and
14 (data not shown). In contrast, CFU-C chimerism in
the BM reached only 5% after 14 days of parabiosis
(Figure 4A). Similar levels of BM chimerism were reported
in mice joined for up to 16 weeks (Wagers et al., 2002). In
extramedullary tissues of parabiotic mice, the highest
level of HPC chimerism was in the spleen (40 ± 7%), and
then the lungs (31 ± 6%), liver (24 ± 9%), and kidneys
(15 ± 5%), implying that within these organs, tissue-resi-
dent HSPCs are constantly replenished by blood-borne998 Cell 131, 994–1008, November 30, 2007 ª2007 Elsevier IncHSPCs and are turned over within a matter of days. Part-
ner-derived CFU-Cs were undetectable in the small intes-
tine or brain. We also detected marked CFU-C chimerism
(27 ± 1%) in the lymph of parabiotic mice, indicating that
at least some homed HSPCs are not permanently retained
in extramedullary tissues but recirculate freely between
lymph and blood (Figure 4B).
To define the kinetics at which HSPCs enter the lymph
after having accessed extramedullary tissues, we surgi-
cally separated some pairs of mice after 14 days of para-
biosis. After separation, blood chimerism decreased
rapidly, whereas lymph-borne HSPC chimerism was un-
changed during the first 36 hr and declined only thereafter
(Figure 4C). Given this delayed drop in HSPC chimerism,
we estimate that the mean dwell time of HSPCs that
have homed to peripheral tissues is at least 36 hr. This
suggests that many organs are sites of active HSPC traffic
from blood to tissue to lymph, but certain organs recruit
few, if any, circulating HSPCs, at least over the 2 week
time interval tested. Of note, a tracer (1% Evans Blue)
injected directly into femur BM did not appear in any jux-
taposed LN (data not shown) but became rapidly visible
in draining LNs after intracutaneous injection. This is con-
sistent with the long-held notion thatmammalian BM lacks
lymphatic drainage. Thus, HSPCs in the BM egress
directly into the blood, whereas lymph-borne HSPCs
have most likely departed from tissues other than the BM.
Sphingosine 1-Phosphate Receptor S1P1
Regulates the Egress of HSPCs from Tissues
into Lymphatics
Next, we sought to determine whether chemoattractants
guide HPC recirculation. Most chemoattractants that
control leukocyte migration signal through Gai-coupled
receptors that can be inhibited by pertussis toxin (PTX). In-
deed, as early as 2–12 hr after a single PTX injection, we
observed a dramatic drop in the number of lymph-borne
CFU-Cs (Figure 5A). In blood, the number of CFU-Cs.
Figure 4. Recirculation of HSPCs through Multiple Extramedullary, Nonlymphoid Tissues
(A) We parabiosed WT and b-actin-GFP transgenic mice and analyzed them by isolating MNCs from the indicated tissues and testing them for GFP+
and GFPCFU-C content (bar graph). Micrographs show representative brightfield (left) and fluorescence (right) images of host- and partner-derived
CFU-Cs. n = 2–8, mean ± SEM.
(B) CFU-C chimerism in TD lymph of parabiotic mice (n = 4, mean ± SEM).
(C) CFU-C chimerism in PB (closed circles) and TD lymph (open circles) at different time points after surgical separation of parabiotic mice (n = 4–8
experiments, mean ± SEM).was not significantly altered during this time interval; how-
ever, their number increased markedly at 24–96 hr after
PTX injection (Papayannopoulou et al., 2003; data not
shown). Thus, Gai-coupled chemoattractants might playCela role in the long-term recruitment of HSPCs from blood
to tissues. However, our parabiosis experiments predict
that the dwell time of HSPCs within tissues is greater
than 36 hr. This implies that a PTX-induced drop inl 131, 994–1008, November 30, 2007 ª2007 Elsevier Inc. 999
Figure 5. Egress of HSPCs from Extramedullary Tissues into Lymph is PTX Sensitive and Depends on S1P
(A) Effect of PTX on lymph-borne CFUc. Lymph was collected for 8 hr from mice that were previously treated for 2 hr with vehicle or 1 mg PTX, and
CFU-C concentration was measured. n = 4–6 assays.
(B) Effect of FTY720 on lymph-borne MNCs and CFUc. The effect of treatment with S1P receptor antagonist FTY720 (6 hr) onMNC concentration (left
panel, n = 4–7) and CFU-C content (right panel, n = 12–14) in lymph is shown.
(C) Effect of FTY720 in LTx-a/mice. CFU-C assays were performed with thoracic duct MNC collected from LT-a-deficient mice treated with vehicle
or FTY720. Lymph MNCs were collected for 8 hr from FTY720-pretreated mice starting at 6 or 48 hr after the last drug administration. The number of
CFU-Cs per ml of lymph is shown.1000 Cell 131, 994–1008, November 30, 2007 ª2007 Elsevier Inc.
lymph-borne CFU-Cs should only become manifest after
36 hr if migration across the blood-tissue interface is
the only step affected by PTX. The much more rapid
time course of PTX-induced CFU-C disappearance from
lymph implies an essential role for a Gai-coupled signal
that directs tissue-resident HSPCs into draining lym-
phatics.
Egress of tissue-resident lymphocytes into lymphatics is
controlled by S1P1, a Gai-coupled receptor for sphin-
gosine 1-phosphate (S1P) (Massberg and von Andrian,
2006; Rosen and Goetzl, 2005). We found that murine
HSPCs express S1P1, as well as S1P2, S1P3, and S1P4
messenger RNA (mRNA) (Figure S4A). Although quantita-
tive real-time polymerase chain reactin (PCR) showed
that the S1P1 mRNA expression levels are lower on
HSPC subsets compared to B and T cells (Figure S4B),
theyweremuchhigher thanonmyeloid cells, andbothpro-
genitor subsets migrated toward S1P in vitro (Figure S4C).
Thus, we asked whether S1P signaling might influence
HSPC recirculation. Most S1P receptors, including S1P1,
are blocked by the immunosuppressant FTY720, which
induces lymphocyte sequestration in SLOs, causing
profound lymphopenia in blood and lymph (Chiba et al.,
1998; Mandala et al., 2002; Matloubian et al., 2004).
Remarkably, the treatment of mice with FTY720 for 6 hr
nearly abolished lymph-borneCFU-Cs (Figure 5B). Among
themultiple S1P receptors expressedbyHSPCs, S1P1 ap-
peared to play the predominant role for this effect because
SEW2871, which selectively targets S1P1 (Jo et al., 2005),
transiently reduced the appearance of lymph-borne CFU-
Cs to a similar extent as FTY720 (Figure S4D). The disap-
pearance of lymph-borne CFU-Cs in response to S1P
receptor inhibition did not require HSPC sequestration in
SLOs because FTY720 blocked HSPC recirculation also
in LT-a/ mice (Figure 5C). HSPCs reappeared in the
lymph of LT-a/mice within 2 days after the discontinua-
tion of FTY720 treatment (Figure 5C), suggesting that
FTY720 does not affect the viability of HSPCs. Likewise,
FTY720 did not alter the capacity of HSPCs to form colo-
nies in CFU-C assays (data not shown).
Notably, FTY720 not only depleted lymph-borne
HSPCs but also induced a significant (74 ± 5%) drop of
CFU-Cs in the blood (Figure 5D). On the basis of our para-
biosis experiments, a decrease of HSPCmigration across
the blood-tissue interface would translate into a decrease
in lymph CFU-Cs only after 2 days. This suggests that
the drop of blood CFU-Cs alone cannot account for the
disappearance of CFU-Cs from the lymph observedwithin
6 hr after FTY720 treatment. The treatment of mice with
FTY720 over 7 days resulted in a significant increase in
the number of HSPCs residing within extramedullary tis-Cellsues (Figure 5E). Hence, our data imply that S1P recep-
tors, particularly S1P1, regulate the egress of HSPCs
from tissue into the draining lymphatic vasculature. The
number of HSPCs in the BM of FTY720-treated mice
was not significantly altered compared to vehicle-treated
animals (Figure S4E). Hence, the FTY720-induced disap-
pearance of HSPCs from blood was due to the inhibition
of HSPC recirculation from extramedullary tissues. Con-
sistent with this notion, we did not observe a significant
difference in the number of HSPCs mobilized to the blood
in response to G-CSF between mice treated with FTY720
or vehicle (data not shown).
S1P is abundant in blood and lymph but low in lymphoid
and nonlymphoid tissues because of rapid interstitial
degradation by tissue-resident S1P lyase (Schwab et al.,
2005). Extravascular lymphocytes in LNs enter the lymph
in response to steep S1P gradients. This egress step
can be inhibited by the pharmacological blockade of
S1P lyase with 2-acetyl-4-tetrahydroxybutylimidazole
(THI) (Schwab et al., 2005). To test whether S1P degrada-
tion through S1P lyase is also required for HSPC recircu-
lation, we collected lymph from THI-treated mice. As
reported previously (Schwab et al., 2005), THI treatment
resulted in profound lymphopenia in blood and lymph
(data not shown). Concomitantly, lymph-borne HSPCs
were markedly reduced (Figure 5F), indicating that S1P
lyase is required for HSPC passage through tissues.
Tissue-Resident HSPCs Give Rise to Myeloid Cells
in Peripheral Tissues
To test whether recirculating HSPCsmight give rise toma-
ture hematopoietic cells locally within extramedullary tis-
sues, we implanted HSPC-enriched LinGFP+ TD-derived
cells (5 3 105) or HSC-enriched BM-derived Lin
c-Kit+Sca-1+ cells (5 3 104) under the left kidney capsule
of recipient mice (Figures 6A and 6B). Medium without
cells was injected into the contralateral (right) kidney. Six
days later, a sizeable number of GFP+ cells was detected
within the kidney implanted with LinGFP+ TD cells and,
especially, after the implantation of HSC-enriched
BM-derived Linc-Kit+Sca-1+ cells (Figures 6A and 6B).
A significantly lower but stable number of GFP+ cells
was observed in the medium-injected control kidney (p <
0.05, Figure 6A) but also within the blood and the BM, as
assessed by CFU-C assay after the implantation of
Linc-Kit+Sca-1+ cells (Figure 6C). Confocal microscopy
showed that virtually all GFP+ cells in injected kidneys
co-expressed the pan-hematopoietic marker CD45
(suppl. Figure 5A). The majority (>50%) of the GFP+ cells
coexpressed myeloid lineage markers (Figure 6A and
Figures S5A and S5B) and 10% coexpressed B220,(D) Effect of FTY720 on blood-borne MNCs and CFUc. The effect of treatment with FTY720 (6 hr) on MNC concentration (left panel) and CFU-C
frequency (right panel) in PB is shown.
(E) Effect of FTY720 on hepatic CFUc. Liver MNCs were collected frommice treated with vehicle or FTY720 (3 mg/kg) for 7 days. The total number of
CFU-C per liver is given.
(F) Effect of THI on lymph-borne CFUc. The CFU-C content in TD lymph of control mice (vehicle) and animals that had received the S1P lyase inhibitor
THI for 3 days (n = 7–8) is shown.
Results are shown as mean ± SEM.131, 994–1008, November 30, 2007 ª2007 Elsevier Inc. 1001
Figure 6. HSPCs Proliferate and Give Rise to Myeloid Cells in Peripheral Tissues Particularly in Response to TLR Ligands
(A and B) Distinct TD- or BM-derived HSPC-enriched populations were implanted under the left kidney capsule of WT mice with medium or LPS with
or without preincubation for 12 hr as indicated. Medium or LPS without cells was injected under the contralateral control kidney capsule. (A) shows
quantitative analysis of the total number of GFP+ cells (‘‘G’’) and of GFP+ myeloid cells (‘‘M’’) in the left (empty bars and filled circles) and in the right1002 Cell 131, 994–1008, November 30, 2007 ª2007 Elsevier Inc.
whereas no CD3- (T cell lineage) expressing GFP+ cells
were detected (Figure S5A). The absolute numbers of
GFP+ cell with myeloid phenotype were 26- and 14-fold
higher in the kidneys injected with LinGFP+ or Lin
c-Kit+Sca-1+GFP+ cells, respectively, compared to the
contralateral cell-free medium-treated kidneys. This im-
plies that after deposition within tissues, HSPCs have
the capacity to differentiate locally into myeloid lineages.
Cell fusion is not likely to account for this process because
the coexpression of CD45.1 and GFP was never observed
whenGFP+ CD45.2+ HSPC-enriched cells were implanted
into CD45.1+ kidney capsules (data not shown).
Tissue-Resident HSPCs Respond to TLR Ligands
HSPCs express Toll-like receptors (TLRs) and their core-
ceptors, including TLR4, MD-2, and CD14, required for
recognition of bacterial lipopolysaccharide (LPS) from
Gram-negative bacteria (Nagai et al., 2006). In vitro, TLR
signaling drives the differentiation of HSPCs into myeloid
lineages. Migratory HSPCs that encounter TLR ligands
within extramedullary tissues might thus act as a highly
versatile local source to rapidly replenish innate immune
cells during infection.We therefore incubated distinct sub-
sets of TD- or BM-derived HSPC-enriched cell popula-
tions for 12 hr with LPS (10 mg/ml) and implanted them
with LPS underneath the left kidney capsule. LPS (10
mg/ml) without HSPCs was injected into the contralateral
(control) kidney (Figures 6A and 6B). Six days after implan-
tation, large numbers of GFP+ cells were present in all kid-
neys injected with GFP+ HSPCs subsets (Figures 6A and
6B). These cells were typically located in clusters, each
comprising up to 400 cells. Similar findings were ob-
tained when we instilled LPS beneath the kidney capsule
immediately prior to the implantation of HSPCs that were
not previously incubated with LPS (Figure 6A). The highest
numbers of GFP+ cells were observed after implantation
of HSC-enriched Linc-Kit+sca-1+ cells (104), whereas
HSC-depleted Linc-Kit+sca-1 cells (enriched in CMPs)
gave rise to comparably lower numbers of GFP+ cells.
In the presence of LPS,more than 95%of theGFP+ cells
coexpressed myeloid lineage markers (Figures 6A and
6B).Most cells (>70%of all GFP+ cells) expressed the den-
dritic cellmarkerCD11c (Figures 6Dand6E, FigureS5C). A
small subset (10%) ofGFP+ cells expressedGr-1 at inter-
mediate to high levels, indicative ofmonocyte and/ormac-
rophage and/or granulocyte differentiation, whereas very
few (<1%) GFP+ myeloid cells were stained with 120G8
mAb, which recognizes plasmacytoid dendritic cells (Fig-Cellures 6D and 6E, Figure S5C, and data not shown). Most
of the GFP+ clusters contained either CD11c+ or Gr-1+
cells, and < 10% of the clusters contained a mixture of
both subsets. A sizeable fraction (>15%) of GFP+ cells
expressed neither CD11c nor Gr-1, suggesting that
some cells remained either undifferentiated or gave rise
to other leukocyte subsets.
In all instances, the numbers of all GFP+ cells and of
myeloid GFP+ cells were significantly higher after the
implantation of HSPCs together with LPS compared to
kidneys injected with the same subset of GFP+ HSPCs
without LPS (Figure 6A), suggesting their local prolifera-
tion after TLR ligand engagement. When recipient mice
were treated with bromodeoxyuridine (BrDU) after the
implantation of HSPC-enriched GFP+ cells, the majority
of the cells of each of the GFP+ clusters had incorporated
BrDU into their nucleus (Figure 6F). Similar findings were
obtained when clusters were stained for the proliferation
marker Ki-67 (Figure 6F), implying that in the presence of
TLR ligands HSPCs proliferate locally. The engagement
of LPS also reduced the exit of clonogenic HSPCs out of
peripheral tissues because the number of donor-derived
GFP+ CFU-Cs was significantly reduced in both peripheral
blood and BM after the implantation of LPS-pretreated
cells (Figure 6C). Along these lines, the number of GFP+
cells in the control kidneys (injected with medium or LPS
without cells), was significantly higher in mice injected
with medium as compared to LPS-treated mice. Although
the overall number of donor-derived cells was low in the
control kidneys injected with LPS without HSPCs, we
detected GFP+Ki-67+ myeloid clusters in these kidneys
(Figure 6F), providing additional in vivo evidence for the
concept of HSPC migration to peripheral tissues contrib-
uting to myeloid defense in inflamed organs.
LPS Interferes with S1P-S1P1 Signaling
in Recirculating HSPCs
Finally, we askedwhether TLR stimulationmightmodulate
the capacity of HSPCs to migrate toward S1P gradients.
We sorted Lin or Linc-Kit+ TD cells and measured
S1P1 mRNA levels after incubation with LPS or medium
for 12 hr. Compared with medium-treated cells, TD-de-
rived Lin and Linc-Kit+ TD cells that had been exposed
to LPS, had 2- to 3-fold-reduced S1P1 transcript levels
(Figure 7A, p < 0.05). The downregulation of S1P1 in re-
sponse to LPS was paralleled by the failure of LPS-treated
HSPCs to chemotax toward gradient of S1P, whereas mi-
grationtowardCXCL12/SDF-1awasenhanced (Figure7B).(control, open circles) kidney. ‘‘*’’ indicates p < 0.05 versus control kidney and ‘‘#’’ indicates p < 0.05 versus medium. Mean ± SEM is shown; n = 3
experiments. (B) shows representative confocal images showing the expression of GFP and reactivity with a mixture of mAbs to myeloid markers
(CD11c, CD11b, F4/80, Gr-1) 6 days after implantation. Scale bars represent 50 mm.
(C) Detection of GFP+ (donor-derived) CFU-C within the BM (left) and PB (right) after the implantation of Linc-Kit+Sca-1+ cells preincubated with
medium or LPS for 12 hr. Mean ± SEM is shown; n = 3 experiments.
(D and E) HSPC-enriched Linc-Kit+ GFP+ cells were implanted into the left kidney capsule of WT recipient mice together with LPS. (D) shows rep-
resentative micrographs showing the expression of GFP, Gr-1, CD11c, or the PDC marker 120G8 in the kidney 6 days later. Scale bars represent
50 mm. (E) shows relative subset frequencies among GFP+ cells in serial kidney sections. Mean ± SEM is shown; n = 3 experiments.
(F) Representative confocal images showing expression of GFP, incorporation of BrDU, and expression of Ki-67 6 days after implantation of the
indicated HSPC populations. Scale bars represent 10 mm. Arrows indicate GFP+ BrDU+ cells, and arrow heads show GFP BrDU+ cells.131, 994–1008, November 30, 2007 ª2007 Elsevier Inc. 1003
Figure 7. A TLR Ligand Reduces the Capacity of HSPCs to Migrate to Sphingosine 1-Phosphate
(A) Quantitative PCR analysis of S1P1mRNA expression bymedium- or LPS-treated Lin
 or Linc-Kit+ TD-derived cells. The amount of S1P1mRNA is
expressed as relative amount of LPS-treated cells normalized to Glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Experiments were
performed in quadruplicate, and ‘‘*’’ indicates p < 0.05. Results are shown as mean ± SEM.
(B) Lin BM-derived cells pretreated for 12 hr with LPS or medium were tested for their ability to migrate to 100 nM S1P or to 50 nM CXCL12/SDF-1a.
Migration to the lower chamber was determined by flow cytometry and is given as percentage of the number of input cells (n = 3 experiments per
group). ‘‘*’’ indicates p < 0.05 versus SDF-1a. Results are shown as mean ± SEM.
(C) Schematic model illustrating the trafficking of migratory HSPCs under physiological conditions and during an inflammation (for details, see
main text).Hence, LPS recognition not only triggers local proliferation
and differentiation but also leads to the retention of HSPCs
within extramedullary tissues (Figure 6C), at least in part by
interfering with S1P-S1P1-dependent signaling.
DISCUSSION
Our data suggest that extramedullary tissues are constitu-
tively surveyed by a pool of recirculating hematopoietic1004 Cell 131, 994–1008, November 30, 2007 ª2007 Elsevier Inprogenitors that are highly versatile and can respond rap-
idly to distress signals from the local microenvironment
(Figure 7C). Naive T and B lymphocytes, another popula-
tion of recirculating cells, gain access to the lymphatic
vasculature after homing to SLOs, which they reach
through specialized postcapillary venules, the high endo-
thelial venule (HEV) (von Andrian and Mackay, 2000).
However, HSPCs can be recovered from TD lymph of lym-
photoxin-a-deficient mice that lack HEVs and SLOs (Dec.
Togni et al., 1994). This implies that blood-borne HSPCs
do not require SLOs to access lymphatics. Accordingly,
we recovered few, if any, CFU-Cs from pooled LNs. Al-
though HSPCs entering the lymph in peripheral nonlym-
phoid tissues must pass through at least one draining
LN before reaching the TD, lymph-borne HSPCs that
give rise to early CFU-Cs (within 7 days of culture) are ap-
parently not retained in the LN stroma but continue to
travel through efferent lymph conduits into the blood.
This lack of HSPC accumulation in LNs is most likely due
to the fact that HSPCs lack CCR7 (Wright et al., 2002),
which is essential for homing to LNs (Debes et al., 2005;
Forster et al., 1999; Stein et al., 2000). However, HSPCs ex-
press multiple other traffic molecules, including PSGL-1,
VLA-4 (CD49d/CD29), LFA-1 (CD11a/CD18), CD44, and
the chemokine receptor CXCR4, which are likely to con-
tribute to HSPC migration to nonlymphoid tissues, partic-
ularly sites of inflammation (Table S1) (Wright et al., 2002).
Although the recruitment mechanism(s) responsible for
HSPC trafficking from blood into extramyeloid tissues re-
main(s) to be elucidated, our experiments have uncovered
a pivotal role for S1P during the subsequent departure of
tissue-resident HSPCs into lymphatics. S1P plays a key
role in enabling lymphocyte egress from the thymus into
the blood and from SLOs into the lymph (Cyster, 2005;
Massberg and von Andrian, 2006; Rosen and Goetzl,
2005). Our study demonstrates that S1P and its receptors,
in particular S1P1, also regulate HSPC recirculation.
HSPCs disappeared from blood and TD lymph when WT
or lymphotoxin-a-deficient mice were treated with
FTY720. In principle, this effect would be expected with
any treatment that blocks HSPC trafficking from one com-
partment to another, be it from the BM to the blood, from
blood to extramyeloid tissues, or from tissues into the
lymph. However, our parabiosis experiments revealed
that HSPCs need at least 36 hr to transit from the blood
across peripheral tissues into the draining lymph, so treat-
ment effects that block HSPC homing from blood to tis-
sues would only result in reduced lymph-borne CFU-Cs
after this lag time. In contrast, both SEW2871 and
FTY720 treatment depleted HSPCs from the lymph within
only 6 hr, indicating that S1P, acting primarily through
S1P1, controls HSPC exit from nonlymphoid tissues into
the draining lymph vessels. This interpretation is also con-
sistent with the observation that prolonged FTY720 treat-
ment resulted in HSPC accumulation in peripheral tissues,
whereas the number of blood-borne HSPCswas reduced.
Because HSPCs express S1P1 mRNA and chemotax
toward S1P gradients in vitro (Figures S4A–S4C and Fig-
ure 7), it is likely that HSPC-expressed S1P1 mediates
HSPC egress from extramedullary tissue. However, it
should be noted that lymphatic endothelial cells also
express S1P1 (Singer et al., 2005; Wei et al., 2005), which
raises the possibility that S1P might exert additional
control over HSPC trafficking via its action on lymphatic
endothelial cells.
An S1P gradient between lymphoid tissue and lymph
fluid is required for lymphocyte egress from LN (SchwabCellet al., 2005). Interstitial tissue fluids contain low levels of
S1P, whereas extracellular S1P concentrations in lymph
and plasma are high (Cyster, 2005; Schwab et al., 2005).
Although plasma S1P is mainly produced by hematopoi-
etic cells, high lymph S1P levels are maintained by a non-
hematopoietic, radiation-resistant source (Pappu et al.,
2007). The S1P gradient between LNs and lymph fluid
is maintained by the S1P-degrading enzyme S1P lyase
(Schwab et al., 2005), which is abundant in most tissues
and cell types except in platelets and erythrocytes (Pappu
et al., 2007). Our present findings suggest that S1P lyase is
similarly essential for the egress of HSPCs from nonlym-
phoid extramedullary tissues. S1P gradients are also
required for the migration of bilateral heart progenitors in
zebrafish (Kupperman et al., 2000). Hence, guidance sig-
nals provided by extracellular lipids, such as S1P, might
represent a conserved navigation mechanism for migrat-
ing stem and progenitor cell populations that is utilized
by vertebrates and invertebrates alike.
What is the functional relevance of HSPC trafficking in
adults? The recirculation of HSPCs between the BM and
blood is believed to be important for the maintenance of
hematopoietic homeostasis in dispersed BM cavities
(Wright et al., 2001b). However, the role of the migratory
pool of HSPCs that percolate constitutively through extra-
medullary tissues and then return to the blood via the TD is
less obvious. Our kidney capsule transplantation experi-
ments show that even in the absence of inflammation,
recirculating HSPCs divide locally in peripheral tissues
and differentiate intomaturemyeloid cells. HomedHSPCs
might thus help to constitutively replenish the diverse pop-
ulation of tissue-resident leukocytes that perform multiple
essential functions in peripheral organs, including, e.g.,
the removal of dead cells and debris.
Given the diverse activities of leukocytes in the context
of tissue damage and immune defense, it would seem
plausible that HSPCs might possess the ability to sense
and respond to situations, such as tissue damage and
infections, that require the rapid influx of large numbers
of innate immune cells. Indeed, HSPCs express TLR2
and TLR4 (Nagai et al., 2006), which sense pathogen-
associated molecular patterns, such as peptidoglycan
and lipoteichoic acid from Gram-positive bacteria and
LPS from Gram-negative bacteria, respectively (Hoshino
et al., 1999). It was shown in vitro that the incubation of
both primitive and committed HSPCs with TLR ligands
triggers HSPC proliferation and rapid myeloid differentia-
tion. On the basis of this discovery, it was hypothesized
that this mechanism could provide a means for boosting
innate immunity during life-threatening infections, where
microbial components either access the circulation and
reach the BM or where dispersed stem and progenitor
cells sense foreignmaterials outside themarrow compart-
ment and become locally converted to innate effector cells
(Nagai et al., 2006). In fact, we show the existence of
a migratory pool of HSPCs that constitutively survey
peripheral tissues. Our experiments indicate that once
these cells sensemicrobial danger signals, they proliferate131, 994–1008, November 30, 2007 ª2007 Elsevier Inc. 1005
vigorously and boost the local supply of innate effector
cells. Thus, the migratory pool of HSPCs might act as
a source of highly versatile stem and progenitor cells
that can respond to danger signals locally within tissues
before the information has spread to the BM. Notably,
TLR stimulation also blocks HSPC egress from inflamed
tissues and abolishes HSPC chemotaxis to S1P in vitro.
Hence, TLR-induced changes in S1P receptor expression
regulate the dwell time of HSPCs in inflamed tissues and
thereby act as a rheostat that can boost local leukocyte
generation.
In conclusion, we show here that HSPCs constitutively
survey extramedullary nonlymphoid tissues. Our results
raise the possibility that in the absence of infection, migra-
tory HSPCs contribute to the continuous restoration of
specialized hematopoietic cells that reside in peripheral
tissues. During tissue infection, the migratory pool of
HSPCs might act as an immediate and highly adaptive
source of progenitor cells that proliferate locally and gen-
erate innate immune effector cells. It will be important to
determine how HSPC traffic within peripheral tissues is
influenced by andmight modulate the course of infectious




Thoracic duct cannulation was performed as described previously
(Ionac, 2003). Where indicated, mice were treated with PTX (50 mg/kg
iv, 2 hr prior to cannulation), FTY720 (1 mg/kg ip, 6 hr prior to cannula-
tion), SEW2871 [20mg/kg 6 hr prior to cannulation (Wei et al., 2005)], or
THI (drinking water with 10 g/L glucose plus 50 mg/ml THI for 3 days
prior to cannulation).
Parabiosis
Six- to eight-week-old sex- and age-matched C57BL/6 WT and
b-actin/GFP mice (Wright et al., 2001a) were joined at the flanks as
described (Wright et al., 2001b). Where indicated, mice were surgically
separated prior to the collection of TD lymph.
Colony-Forming Unit Assays
MNCs or sorted Lin+, Linc-Kit and Linc-Kit+ cells isolated from TD
lymph, BM, and peripheral blood (PB) were assessed for CFU-C
content by the culturing of 6 3 106 cells in methylcellulose-containing
MethoCult M3434 medium (StemCell Technologies [Vancouver,
Canada]) as reported (Papayannopoulou et al., 2003).
Primary and Secondary Transplantation Assays
TD MNCs (2 3 107) collected from CD45.2+ C57BL/6 or nude mice
were injected into sublethally (900 rad) or lethally (1300 rad) irradiated
CD45.1+ or Rag2/gc/mice. Where indicated, 105 rescue BM cells
from Rag2/gc/ donors were coinjected with TD MNCs. After 6
weeks, blood was obtained from the retro-orbital plexus, and the pres-
ence of donor-derivedmyeloid cells (CD45.2+Gr-1+) or T cells (TCR-b+)
was assessed by flow cytometry. For secondary transplantation,
2 3 107 CD45.2+ TD MNCs were isolated and transplanted into suble-
thally irradiated (900 rad) CD45.1+ congenic recipients. Twelve weeks
after reconstitution, recipients with pronounced chimerism of peripheral
blood granulocytes were sacrificed, and donor-derived (CD45.1) BM
cells were sorted with a FACSAria cell sorter (BD Biosciences) and
transplanted into lethally irradiated CD45.1+ secondary recipients.1006 Cell 131, 994–1008, November 30, 2007 ª2007 Elsevier InTen weeks later, chimerism among peripheral blood granulocytes,
T cells, and B cells (CD19+ B220+) was assessed by FACS analysis.
In Vivo Assessment of HSPC Differentiation
TD-derived GFP+CD45.2+Lin (53 105), GFP+CD45.2+Linc-Kit+ (53
105), BM-derived GFP+ Linc-Kit+ (53 105), Linc-Kit+sca-1 (53 104
or 53 105), or Linc-Kit+sca-1+ (53 104) were implanted under the left
kidney capsule of CD45.1+ congenic recipient mice. Where indicated,
the cells were preincubated with medium containing stem cell factor
(R&D, 20 ng/ml), Flt-3 ligand (R&D, 100 ng/ml) in the absence or pres-
ence of LPS (Sigma, 10 mg/ml), and CD14-Fc (R&D, 1 mg/ml) for 12 hr
before implantation or were not pre-exposed to LPS but injected into
the kidneys together with LPS (10 mg/ml). The right kidney was used
as a control and was injected with mediumwith or without LPS (Sigma,
10 mg/ml) and CD14-Fc (R&D, 1 mg/ml). Where indicated, the recipient
mice received 1 mg/day BrDU i.p (BD Biosciences [San Jose, CA]) on
days 4, 5, and 6 after implantation. Six days after the implantation of
the cells, mice were perfusion fixed and the kidneys were harvested
and quantitatively analyzed by confocal laser scanning microscopy.
To this end, five serial sections (each 30 mm thick) were obtained
from the anterior aspect of the kidney and stained with fluorescently
tagged anti-GFP (Rockland [Gilbertsville, PA]), anti-CD45, anti-
CD45.1, anti-CD45.2, anti-Gr-1(Ly6G/C), anti-CD11c, anti-B220,
anti-CD3 (all from BD Biosciences), mouse anti-human Ki-67 antibody
(B56, crossreacting with mouse Ki-67, BD Biosciences) and anti-pDC/
IPC (clone 120G8.04, Dendritics [France]) as indicated. So that mye-
loid differentiation could be detected, sections were stained with
a panel of monoclonal antibody (mAb) against myeloid lineagemarkers
[CD11b, CD11c, F4/80, Gr-1(Ly6G/C)] and then APC-conjugated
streptavidin (BD Biosciences). BrDU in situ detection was performed
according to the manufacturer’s recommendations with biotin-labeled
antibody recognizing BrDU (BrDU in situ detection kit, BDBiosciences)
and APC-conjugated streptavidin (BD Biosciences).
Statistical Analyses
Quantitative results are expressed as means ± the standard error of
the mean (SEM) unless otherwise indicated. The Mann-Whitney test
was used for the determination of the significance of differences be-
tween means. Statistical significance was assumed at p < 0.05.
Supplemental Data
Supplemental Data include Experimental Procedures, five figures, one
table, and three movies and can be found with this article online at
http://www.cell.com/cgi/content/full/131/5/994/DC1/.
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